Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2484 • 2019 ACR/ARP Annual Meeting
Gender Influence on Treatment Effectiveness in Psoriatic Arthritis
Diego Benavent¹, Chamaida Plasencia ², Victoria Navarro-Compán ³, Diana Peiteado ⁴, Alejandro Villalba ⁵, Laura Nuño ⁶, Elisa Fernández ⁷ and Alejandro Balsa ², ¹Hospital Universitario La Paz, Madrid, Spain, ²Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, ³University Hospital La Paz, IdiPaz, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, ⁵FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, ⁶Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, ⁷Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain
Background/Purpose: Gender has been lately suggested as influential in the response to treatment with biological drugs in spondyloarthritis. However, data about the association between gender…
Abstract Number: 2505 • 2019 ACR/ARP Annual Meeting
Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina
Luciano Fernando Lo Giudice¹, Maria Laura Acosta Felquer ¹, Luis Daniel Mazzuoccolo ², Maria Laura Galimberti ² and Enrique Soriano ³, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: As psoriasis (Pso) commonly precedes psoriatic arthritis (PsA), an important unanswered question is whether treatment of Pso might influence the development of PsA in…
Abstract Number: 2877 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis
Kim Papp¹, Melinda Gooderham ², Akimichi Morita ³, Alan Kivitz ⁴, Ranjeeta Sinvhal ⁵, Andrew Topp ⁵, Graham Heap ⁵, Ann Eldred ⁵ and Philip Mease ⁶, ¹K. Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, Waterloo, ON, Canada, ²2School of Medicine, Queen’s University, Kingston, ON and Skin Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada, ³Dept of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵AbbVie Inc., North Chicago, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is characterized by peripheral synovitis, enthesitis, dactylitis and spondylitis, and IL-23 is involved in the pathogenesis of these conditions either directly…
Abstract Number: 248 • 2019 ACR/ARP Annual Meeting
Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) —a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel
Caroline Swift ¹, Yvonne Viteri², Gail Bridges ³, Mary Dorholt ⁴ and Monal Kohli ⁵, ¹Express Scripts, St. Louis, MO, ²Accredo, Northvale, NJ, ³Accredo, Memphis, TN, ⁴Accredo, Maple Grove, MN, ⁵Express Scripts, Franklin Lakes, NJ
Background/Purpose: Medication adherence to biologic DMARDs has been associated with optimal clinical outcomes. Adherence varies with primary dispensing channel among rheumatoid arthritis patients. Prior studies…
Abstract Number: 1003 • 2019 ACR/ARP Annual Meeting
TNF Inhibitors Improves Arterial Stiffness with Cs DMARDs-resistant Active Psoriatic Arthritis: A Cohort Extended Study
Kensuke Kume¹, kanzo amano ¹, toshikatsu kanazawa ¹, susumu yamada ¹ and kazuhiko hatta ¹, ¹Department of Rheumatology/Hiroshima Clinic, Hiroshima, Hiroshima, Japan
Background/Purpose: Background/ Patients with psoriatic arthritis (PsA) have an increased cardiovascular (CV) risk. We should have strategies for primary cardiovascular prevention in PsA1). But there…
Abstract Number: 1175 • 2019 ACR/ARP Annual Meeting
Periarticular Inflammation and Bone Marrow Oedema Are Important in the Evaluation of Enthesitis on MRI in Patients with Peripheral and Axial SpA
Xenofon Baraliakos¹, Philipp Sewerin ², Eugenio de Miguel ³, Christine Kleinmond ⁴, Ankita Shekhawat ⁵, Annette Wiedon ⁶ and Frank Behrens ⁷, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ²Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁴ClinProject GmbH, Eurasburg, Germany, ⁵Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁶Novartis Pharma GmbH, Nürnberg, Germany, ⁷CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany
Background/Purpose: Enthesitis is a hallmark feature of Spondyloarthritis (SpA), and frequently localizes at the Achilles tendon1. Enthesitis is predominantly measured with clinical scores like Leeds…
Abstract Number: 1503 • 2019 ACR/ARP Annual Meeting
Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials
Mark Genovese¹, Hideto Kameda ², Proton Rahman ³, Juan Cañete ⁴, Sandra Garces ⁵, Wen Xu ⁶, Matthew M. Hufford ⁵ and Bernard Combe ⁷, ¹Stanford University, Stanford, CA, ²Toho University, Tokyo, Japan, Tokyo, Japan, ³Memorial University, Newfoundland, NL, Canada, ⁴Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, ⁷CHU Montpellier, Montpellier University, Montpellier, France
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that specifically targets IL-17A. Pooled safety data from IXE studies in moderate-to-severe plaque psoriasis (PsO) and psoriatic…
Abstract Number: 1553 • 2019 ACR/ARP Annual Meeting
Impact of Peripheral Swollen and Tender Joints at Baseline on Response to Treatment with Secukinumab in Ankylosing Spondylitis
Philip Mease¹, Atul Deodhar ², Renato Calheiros ³, Xiangyi Meng ³, Todd Fox ⁴ and Xenofon Baraliakos ⁵, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany
Background/Purpose: AS is a chronic, inflammatory disease of the axial skeleton associated with pain, stiffness, disability, and reduced quality of life (QOL).1 AS is defined…
Abstract Number: 2445 • 2019 ACR/ARP Annual Meeting
Enthesitis, Dactylitis, and Axial Disease in Psoriatic Arthritis (PsA): Impact on Patient Quality of Life and Work Productivity
Jessica Walsh¹, Alexis Ogdie ², Kaleb Michaud ³, Steve Peterson ⁴, Elizabeth Holdsworth ⁵, Chetan Karyekar ⁴, Nicola Booth ⁶, Jessalyn Kemp ⁷, Soumya Chakravarty ⁸, Shelly Kafka ⁹ and Laure Gossec ¹⁰, ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Janssen Global Services, LLC, Horsham, PA, ⁵Adelphi Real World, Manchester, England, United Kingdom, ⁶Adelphi Real World, Bollington, United Kingdom, ⁷Adelphi Real World, Manchester, United Kingdom, ⁸Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA, ⁹Janssen Scientific Affairs, LLC, Horsham, PA, ¹⁰Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: PsA is a chronic, inflammatory disease characterised by peripheral arthritis, axial disease, dactylitis, enthesitis and skin and nail psoriasis. The impact of skin and…
Abstract Number: 2465 • 2019 ACR/ARP Annual Meeting
Reliability and Validity of the Self‐Administered Comorbidity Questionnaire in Psoriatic Arthritis
Didem Erdem¹, Halise Hande Gezer ², Sevtap Acer Kasman ¹ and Mehmet Tuncay Duruoz ¹, ¹Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Turkey, ²Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Istanbul, Turkey
Background/Purpose: The Self‐Administered Comorbidity Questionnaire (SCQ) is a self-report questionnaire. It assesses 13 common medical conditions and the impact of comorbidities on functional status (1).…
Abstract Number: 2485 • 2019 ACR/ARP Annual Meeting
Red Cell Distribution Width Positively Correlates with Atherosclerotic Cardiovascular Disease Risk Score in Psoriatic Arthritis and Decreases with BDMARD Therapy
Angela Gupta¹, Sofi Damjanovska ², David Zidar ³, Donald Anthony ⁴ and Maya Mattar ³, ¹Case Western Reserve University, Cleveland, ²Case Western Reserve University, Cleveland Heights, OH, ³Louis Stokes Cleveland VA Medical Center, Cleveland, OH, ⁴Case Western Reserve University, Cleveland, OH
Background/Purpose: Red blood cell distribution width (RDW) is a parameter that measures variation in red blood cell size and volume. It is elevated when there…
Abstract Number: 2506 • 2019 ACR/ARP Annual Meeting
The ‘Severity of Nail Psoriasis Score’ (SNAPS) Is Feasible, Reliable and Demonstrates Construct Validity Against the mNAPSI in an Observational Cohort of Patients with Psoriatic Arthritis
Anna Antony¹, Darren Hart ², Charlotte Cavill ³, Eleanor Korendowych ⁴, Neil McHugh ⁵, Christopher Lovell ⁴ and William Tillett ⁴, ¹Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Melbourne, Victoria, Australia, ²Department of Clinical Measurement, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, England, United Kingdom, ³Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, United Kingdom, ⁴Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, England, United Kingdom, ⁵University of Bath, Bath, England, United Kingdom
Background/Purpose: Background: Longitudinal assessment of psoriatic nail dystrophy and its response to treatment is limited outside of research settings due to the complexity of existing…
Abstract Number: 2878 • 2019 ACR/ARP Annual Meeting
Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
Philip Mease¹, Saima Chohan ², Ferran J. García Fructuoso ³, Alice Gottlieb ⁴, Richard C. Chou ⁵, Alan Mendelsohn ⁶, Rocco Ballerini ⁶ and Michael E. Luggen ⁷, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, AZ, USA, Phoenix, AZ, ³Hospital CIMA Sanitas, Barcelona, Spain, Barcelona, Spain, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ⁵University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁶Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁷Cincinnati Rheumatic Disease Study Group, Inc. and University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cincinnati, OH
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved for moderate-to-severe plaque psoriasis treatment and is under investigation for PsA. This study evaluated the…
Abstract Number: 259 • 2019 ACR/ARP Annual Meeting
Describing Treatment Patterns and Healthcare Costs in Newly Diagnosed Psoriatic Arthritis Patients by Physician Specialty
Joseph Tkacz ¹, Ervant Maksabedian², Philip Chan ¹, Brendan Limone ¹, Alexis Ogdie ³, Elaine Karis ⁴ and Bradley Stolshek ², ¹IBM Watson, Bethesda, MD, ²Amgen Inc., Thousand Oaks, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Amgen Inc, Thousand Oaks, CA
Background/Purpose: The clinical heterogeneity of psoriatic arthritis (PsA) presents a variety of diagnostic and treatment challenges, which may be reflected in the way different health…
Abstract Number: 1004 • 2019 ACR/ARP Annual Meeting
Genetic Ablation of γδTCR Inhibits IL-23-induced Neutrophilia and Attenuates Epidermal Hyperplasia, Synovitis, Onycholysis and Enthesitis Associated with Psoriatic Arthritis
Cuong Nguyen¹, Trevor Chan ², Ilias Tagkopoulos ², Matthias Eberl ³ and Iannis Adamopoulos ¹, ¹Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, Sacramento, CA, ²University of California, Davis, Department of Computer Science, California, USA, Davis, CA, ³Division of Infection and Immunity, School of Medicine and Systems Immunity Research Institute, Cardiff University, Cardiff CF14 4XN, United Kingdom, Cardiff, United Kingdom
Background/Purpose: γδ T cells are non-conventional lymphocytes that straddle between innate and adaptive immunity. Although γδ T cells have been implicated in psoriatic arthritis, the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].